J 2019

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study

ŠUMOVÁ, Barbora, Lucie Andrés CEREZO, Lenka SZCZUKOVÁ, Lucie NEKVINDOVÁ, Michal UHER et. al.

Basic information

Original name

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study

Authors

ŠUMOVÁ, Barbora (203 Czech Republic), Lucie Andrés CEREZO (203 Czech Republic), Lenka SZCZUKOVÁ (203 Czech Republic, belonging to the institution), Lucie NEKVINDOVÁ (203 Czech Republic, belonging to the institution), Michal UHER (203 Czech Republic, belonging to the institution), Hana HULEJOVÁ (203 Czech Republic), Radka MORAVCOVÁ (203 Czech Republic), Mariam GRIGORIAN (208 Denmark), Karel PAVELKA (203 Czech Republic), Jiří VENCOVSKÝ (203 Czech Republic), Ladislav ŠENOLT (203 Czech Republic) and Jakub ZÁVADA (203 Czech Republic, guarantor)

Edition

Rheumatology International, Heidelberg, Springer, 2019, 0172-8172

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30226 Rheumatology

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.984

RIV identification code

RIV/00216224:14110/19:00109000

Organization unit

Faculty of Medicine

DOI

UT WoS

000458566100007

Keywords in English

Biomarkers; SLE; S100 proteins; Disease activity

Tags

Tags

International impact, Reviewed
Změněno: 15/4/2019 14:50, Soňa Böhmová

Abstract

V originále

S100 proteins are currently being investigated as potential diagnostic and prognostic biomarkers of several cancers and inflammatory diseases. The aims of this study were to analyse the plasma levels of S100A4, S100A8/9 and S100A12 in patients with incomplete systemic lupus erythematosus (iSLE), in patients with established SLE and in healthy controls (HCs) and to investigate the potential utility of the S100 proteins as diagnostic or activity-specific biomarkers in SLE. Plasma levels were measured by ELISA in a cross-sectional cohort study of 44 patients with SLE, 8 patients with iSLE and 43 HCs. Disease activity was assessed using the SLEDAI-2K. The mean levels of all S100 proteins were significantly higher in SLE patients compared to HCs. In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were also significantly higher compared to HCs. There were no significant differences in S100 levels between the iSLE and SLE patients. Plasma S100 proteins levels effectively discriminated between SLE patients and HCs. The area under the curve (AUC) for S100A4, S100A8/9 and S100A12 plasma levels was 0.989 (95% CI 0.976-1.000), 0.678 (95% CI 0.563-0.792) and 0.807 (95% CI 0.715-0.899), respectively. S100 levels did not differentiate between patients with high and low disease activity. Only the S100A12 levels were significantly associated with SLEDAI-2K and with cSLEDAI-2K. S100 proteins were significantly higher in SLE patients compared HCs and particularly S100A4 could be proposed as a potential diagnostic biomarker for SLE.